Company intelligence

HEPA

Hepion Pharmaceuticals, Inc. · NASDAQ · Healthcare

Price$0.04+5.13% · +$0.00

Market cap476.43KEquity value

P / E-0.1Trailing ratio

Volume93Latest session

Market data

HEPA price chart

TradingView

Related signals

1 min delayed

Browse public HEPA signals with their source context and measured market impact. Open any signal for its permanent analysis page.

HEPAJul 22, 2024-9.84% since signal

Fatty-Liver Focused Hepion Pharmaceuticals Agrees To Merge With Israel-Based Parkinson's Disease Drug Developer

Hepion merges with Pharma Two B for $58.5 million. Pharma Two B develops P2B001 for Parkinson’s Disease. New company will operate as Pharma Two B post-merger. P2B001 aims to provide safer treatment for Parkinson’s patients. Hepion secured $2.9 million through a private placement to investors.

View signal analysis

HEPAJul 22, 2024-9.83% since signal

Fatty-Liver Focused Hepion Pharmaceuticals Agrees To Merge With Israel-Based Parkinson's Disease Drug Developer

Hepion Pharmaceuticals merges with Pharma Two B for $58.5 million valuation. Combined entity will operate as Pharma Two B and aim for Nasdaq listing. P2B001 targets unmet needs in Parkinson's treatment with once-daily regimen. Hepion initiates $2.9 million private placement of senior notes. Stock price shows a 1.96% increase during premarket trading.

View signal analysis

Research